Press Releases
Search by Year
-
10 Mar 2023
BioFire Defense partners with BARDA to accelerate development of the SPECIFIC REVEAL™ Rapid AST System
BioFire Defense, LLC, has received a contract from the BARDA (Biomedical Advanced Research and Development Authority) to accelerate development of the Specific Diagnostics SPECIFIC REVEAL™ Rapid AST System that can deliver phenotypic results in an average of five and a half hours from positive blood cultures.
-
08 Mar 2023
bioMérieux 2022 Financial Results
bioMérieux announced a strong performance in 2022 with robust full-year sales at €3,589 million with a reported growth of +6.3% and an almost neutral organic growth of +0.2%.
-
08 Feb 2023
US FDA 510(k) Clearance and CLIA-waiver for the fast and innovative BIOFIRE® SPOTFIRE® System
bioMérieux receives US FDA 510(k) Clearance and CLIA-waiver for the fast and innovative BIOFIRE® SPOTFIRE® System and its BIOFIRE® SPOTFIRE® Respiratory (R) Panel and will be submitting the BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini for 510(k) clearance.
-
01 Feb 2023
MAESTRIA™, a new generation microbiology middleware developed by bioMérieux
bioMérieux, a world leader in the field of in vitro diagnostics, launches MAESTRIA™. This new generation middleware for the microbiology laboratory aims at providing a central software tool for the workflow management of all routine activities.
-
20 Dec 2022
CE-marking of VIDAS® KUBE™, the next generation system in the VIDAS® immunoassay portfolio
VIDAS® KUBE™ is the next generation automated immunoassay system for the renowned VIDAS® range. It will benefit clinical labs and food industries by providing results to help speed up patient care and protect consumers.
-
15 Dec 2022
2022 increased outlook and 2023 preview guidance
bioMérieux, a world leader in the field of in vitro diagnostics, today released its adjusted outlook for full-year 2022 and a preview of 2023 guidance.
-
16 Nov 2022
Survey bioMérieux OpinionWay - Antimicrobial Resistance and diagnostic tests
To mark World Antimicrobial Awareness Week organized by the WHO from November 18-24, bioMérieux presents the results of a bioMérieux/OpinionWay survey on the general public's knowledge of antimicrobial resistance and the use of diagnostic tests in France.
-
26 Oct 2022
Third-quarter 2022 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, releases its business review for the nine months ended September 30, 2022.
-
26 Sep 2022
New survey shows low adherence to guidelines in sepsis care puts patients at risk
To mark Sepsis Awareness Month, bioMérieux, a world leader in in vitro diagnostics with a long-standing commitment to the fight against sepsis, and the UK Sepsis Trust, an internationally renowned charity, have released new survey data of health professionals to assess their knowledge and practice in the management of sepsis. This survey was commissioned among 368 doctors across six European countries.
-
31 Aug 2022
First-Half 2022 Results
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 30 under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2022.